Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists

This publication has 134 references indexed in Scilit:

• Myelosuppression by sunitinib is flt-3 genotype dependent
  British Journal of Cancer, 2010
• Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial
  The Lancet Oncology, 2010
• The biology and treatment of EML4-ALK non-small cell lung cancer
  European Journal of Cancer, 2010
• Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer
  British Journal of Cancer, 2009
• Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
  Oncogene, 2009
• MET as a target for treatment of chest tumors
  Lung Cancer, 2009
• BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
  Oncogene, 2008
• Epidermal growth factor receptor mutations in lung cancer
  Nature Reviews Cancer, 2007
• Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer
  British Journal of Cancer, 2006
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
  The Lancet, 2005